E-viri
Recenzirano
-
Remiszewski, Stacy W; Sambucetti, Lidia C; Bair, Kenneth W; Bontempo, John; Cesarz, David; Chandramouli, Nagarajan; Chen, Ru; Cheung, Min; Cornell-Kennon, Susan; Dean, Karl; Diamantidis, George; France, Dennis; Green, Michael A; Howell, Kobporn Lulu; Kashi, Rina; Kwon, Paul; Lassota, Peter; Martin, Mary S; Mou, Yin; Perez, Lawrence B; Sharma, Sushil; Smith, Troy; Sorensen, Eric; Taplin, Francis; Trogani, Nancy; Versace, Richard; Walker, Heather; Weltchek-Engler, Susan; Wood, Alexander; Wu, Arthur; Atadja, Peter
Journal of medicinal chemistry, 10/2003, Letnik: 46, Številka: 21Journal Article
A series of N-hydroxy-3-phenyl-2-propenamides were prepared as novel inhibitors of human histone deacetylase (HDAC). These compounds were potent enzyme inhibitors, having IC50s < 400 nM in a partially purified enzyme assay. However, potency in cell growth inhibition assays ranged over 2 orders of magnitude in two human carcinoma cell lines. Selected compounds having cellular IC50 < 750 nM were tested for maximum tolerated dose (MTD) and for efficacy in the HCT116 human colon tumor xenograft assay. Four compounds having an MTD ≥ 100 mg/kg were selected for dose−response studies in the HCT116 xenograft model. One compound, 9 (NVP-LAQ824), had significant dose-related activity in the HCT116 colon and A549 lung tumor models, high MTD, and low gross toxicity. On the basis, in part, of these properties, 9 has entered human clinical trials in 2002.
